Blastomycosis clinical trials at University of California Health

• Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases

  open to eligible people ages 18 years and up

  This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

  at UC Davis

Last updated: September 30, 2021